title: [Dimethyl-triazeno-imidazole-carboxamide (DTIC) in combination chemotherapy for childhood neuroblastoma (author's transl)].
abstract: Eight children with state III or IV neuroblastoma were treated with courses of chemotherapy consisting of nitrogen mustard (6 mg/m2), vincristine (2 X 1.5 mg/m2), doxorubicin (40 mg/m2) and dimethyl-triazeno-imidazolecarboxamide (850 mg/m2) every three weeks. Three children died after a median survival of 8 (+/-5) months. Five children (62%) have now survived for a medium duration of 21 (+/-16) months without clinical evidence of disease. These results are far better than previously-achieved survival rates at our department.
mesh_terms: D002675:Child, Preschool; D003606:Dacarbazine / Q000008:administration & dosage / Q000627:therapeutic use*; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007223:Infant; D008297:Male; D008466:Mechlorethamine / Q000008:administration & dosage / Q000627:therapeutic use; D009447:Neuroblastoma / Q000188:drug therapy* / Q000401:mortality; D014226:Triazenes / Q000627:therapeutic use*; D014750:Vincristine / Q000008:administration & dosage / Q000627:therapeutic use
chemical_list: D014226:Triazenes; D008466:Mechlorethamine; D014750:Vincristine; D003606:Dacarbazine; D004317:Doxorubicin
vernacular_title: Chemotherapie bei Neuroblastom im Kindesalter mit einer Dimethyl-Triazeno-Imidazol-Carboxamid-(DTIC-)Kombination.